Preprint
Review

This version is not peer-reviewed.

RAS Inhibition and Renal Arteriolar Remodelling

Submitted:

14 November 2026

Posted:

17 November 2026

You are already at the latest version

Abstract
Purpose of Review: Renin–angiotensin system (RAS) inhibition confers established renal and cardiovascular benefits, yet sustained experimental RAS perturbation can induce concentric renal arteriolar remodelling. Limited human histopathological observations suggest analogous structural changes during treatment, without establishing causation or clinical harm. This review examines the pathological specificity of these findings and the evidence required to distinguish treatment-associated vascular adaptation from clinically consequential injury. Recent Findings: Experimental studies implicate renin-lineage cells in vascular wall expansion, extracellular-matrix accumulation and altered neurovascular organisation. Comparative pharmacological investigations demonstrate that vascular responses vary with the experimental model, treatment intensity and mechanism of RAS suppression. Notably, attenuation of arteriolar hypertrophy through renin-lineage integrin-β1 deletion did not produce corresponding functional renal rescue. Small observational human studies identify treatment-associated differences in afferent arteriolar architecture but lack a validated diagnostic signature. Research published in 2026 further establishes renin-cell-derived nerve growth factor as an organiser of experimental renal neurovascular architecture, without demonstrating treatment-induced hyperinnervation in humans. Summary: Renin-associated vascular remodelling is biologically credible, but treatment-induced human renal arteriolopathy remains unproved. A pathology-centred attribution framework is proposed that distinguishes anatomical observation, mechanistic concordance and causal disease attribution. Its application to biopsy interpretation, together with a staged validation strategy, provides a means of preventing nonspecific vascular morphology from being mistaken for a treatment-induced lesion. Current evidence does not justify modifying guideline-directed RAS inhibition on histopathological grounds alone.
Keywords: 
;  ;  ;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.